Leadership & Scientific Advisory Board
Making cancer more detectable.
Management Team
Dr. Isaac Bright
Chief Executive Officer
Dr. Bright is a results-focused business leader and brings over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics.
Dr. Isaac Bright
Chief Executive Officer
Dr. Bright is a results-focused business leader and brings over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics.
Geoff Hollis
CFO and Company Secretary
Geoff recently spent two years as CFO and Company Secretary of Victory Offices Limited, a leading provider of flexible workspace solutions, leading the company through an IPO on the Australian Stock Exchange.
Geoff Hollis
CFO and Company Secretary
Geoff recently spent two years as CFO and Company Secretary of Victory Offices Limited, a leading provider of flexible workspace solutions, leading the company through an IPO on the Australian Stock Exchange.
Marie Zhang
VP Research & Pre-Clinical Development
Marie Zhang, PhD, MBA, is a problem-solver and an effective scientific leader specializing in pharmaceutical and research reagent product development.
Marie Zhang
VP Research & Pre-Clinical Development
Marie Zhang, PhD, MBA, is a problem-solver and an effective scientific leader specializing in pharmaceutical and research reagent product development.
Yalia Jayalakshmi
Chief Development Officer
Yalia Jayalakshmi, Ph.D. (Jaya) is a biopharmaceutical executive with over 25 years of industry experience in the clinical translation of a wide spectrum of drug, device, nanoparticle delivery and diagnostic imaging product candidates in oncology, ophthalmology and other therapeutic areas.
Yalia Jayalakshmi
Chief Development Officer
Yalia Jayalakshmi, Ph.D. (Jaya) is a biopharmaceutical executive with over 25 years of industry experience in the clinical translation of a wide spectrum of drug, device, nanoparticle delivery and diagnostic imaging product candidates in oncology, ophthalmology and other therapeutic areas.
Experienced Board
Commercially focused team with deep industry & clinical experience.
Robert Proulx
Non-Executive Chairman
Robert is an operationally oriented executive with over 30 years in life science & medical device product development & commercialization and has led the company through recent restructuring and recapitalization efforts.
Robert Proulx
Non-Executive Chairman
Robert is an operationally oriented executive with over 30 years in life science & medical device product development & commercialization and has led the company through recent restructuring and recapitalization efforts.
Michael Harsh
Non-Executive Director
Mike has over 36 years of experience in healthcare technology, focused on diagnostic imaging having served as Vice President and Chief Technology Officer for GE Healthcare.
Michael Harsh
Non-Executive Director
Mike has over 36 years of experience in healthcare technology, focused on diagnostic imaging having served as Vice President and Chief Technology Officer for GE Healthcare.
David Ludvigson
Non-Executive Director
David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems.
David Ludvigson
Non-Executive Director
David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems.
Dianne Angus
Non-Executive Director
Dianne has worked as a senior executive within the biotechnology, agritech and healthcare sectors for over twenty years and currently serves as non-executive director with Neuren Pharmaceuticals Limited (ASX:NEU) and the federal government Grains Research & Development Corporation (GRDC).
Dianne Angus
Non-Executive Director
Dianne has worked as a senior executive within the biotechnology, agritech and healthcare sectors for over twenty years and currently serves as non-executive director with Neuren Pharmaceuticals Limited (ASX:NEU) and the federal government Grains Research & Development Corporation (GRDC).
Mark Van Asten
Non-Executive Director
Mark has over 30 years of experience in the medical diagnostics and life science industry. Much of this time has been specific to international business development, strategic planning and introduction of new technology.
Mark Van Asten
Non-Executive Director
Mark has over 30 years of experience in the medical diagnostics and life science industry. Much of this time has been specific to international business development, strategic planning and introduction of new technology.
Jovanka Naumoska
Non-Executive Director
Jovanka is an Australian legal practitioner with expertise in intellectual property law, corporate law, and corporate governance.
Jovanka Naumoska
Non-Executive Director
Jovanka is an Australian legal practitioner with expertise in intellectual property law, corporate law, and corporate governance.
Scientific Advisory
Collective expertise in oncology, medical imaging, nanotechnology, clinical trial design.
Dr. John Hazle
Chairman, Department of Imaging Physics, MD Anderson Cancer Center
John chairs the scientic advisory board. He is board certifed in medical physics with 30 years in pre-clinical & clinical imaging research. He chairs Cancer Research at UT Graduate School of Biomedical Sciences.
Prof. Lisa Horvath
Director, Department of Medical Oncology, Chris O’Brien Lifehouse
She has an active clinical practice and is involved with a large number of clinical trials in prostate and colorectal cancers in addition to phase I trial work.
Dr. Robert Ivkov
Assistant Professor, Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Dr. Ivkov’s research focuses on the development and characterization of magnetic nanoparticles and AMF-devices for cancer therapy.
Prof. Andrew Scott
Director, Department of Molecular Imaging and Therapy, Austin Health
His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies, and in molecular imaging particularly oncology applications in PET in staging cancer.
Dr. Paul Grint
Chairman, The Innovation Council
Dr. Grint has more than two decades of experience in biologics and small molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology and oncology therapeutic areas.
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.